Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

Phase 3

Completed

• Conditions: Breast Cancer
• Interventions: Drug: Trastuzumab Injectable Solution; Drug: Trastuzumab Injectable Product; Drug: Trastuzumab Injection

• Registration Number: NCT01875367
• Lead Sponsor: Spanish Breast Cancer Research Group

Brief Summary

GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of trastuzumab, and within the SC by the administration through the vial or device self-administration in patients with disseminated breast cancer HER2.

Detailed Description

Approximately 195 patients will be included to receive subcutaneous trastuzumab a fixed dose of 600 mg every 3 weeks for 4 cycles (2 administered from the injection of a vial with a syringe and 2 with the injection device). Following administration of these four cycles, the patient will decide whether or not to continue with the subcutaneous formulation of trastuzumab every 3 weeks until progression (out of the study). Since the randomization in the study until the start with subcutaneous trastuzumab, patients will receive a treatment cycle of intravenous trastuzumab as usual.

Main objective: Proportion of patients indicate a preference for the use of subcutaneous vs intravenous trastuzumab.

This principal primary objective will be analyzed with the answers to questionnaire of experiences and preferences of the patients (Principal endpoint) The duration of the study has been estimated after 34 months.

Study Timeline

• Study First Submitted: 2013-06-07
• Study First Submitted QC: 2013-06-07
• Study First Posted: 2013-06-11
• Study Start: 2013-09-18
• Primary Completion: 2016-11-30
• Study Completion: 2018-04-30
• Results First Submitted: 2020-10-09
• Results First Submitted QC: 2021-01-07
• Results First Posted: 2021-02-01
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-04
• Last Update Posted: 2023-04-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 166

Inclusion Criteria

• Woman, 18 years old or upper.

• Patient with advanced breast cancer with human epidermal growth factor receptor 2 (HER 2) positive histologically confirmed. The criteria for positivity HER 2 are:

  1. immuno-histochemistry (IHC) 3+ (>10% of tumor cells with complete and intense membrane staining)
  2. IHC 2+ with fluorescent in situ hybridization (FISH) / Chromogenic in situ hybridization (CISH) / silver-enhanced in situ hybridization (SISH) + for HER 2 amplification (*)
  3. FISH / CISH / SISH + for HER 2 amplification (*) (*) Defined as the ratio of copies of HER 2/neu and copies of centromere of chromosome 17 (CEP17)> 2.2, or a number of copies of HER 2/neu> 6, as per local laboratory criteria.

• Patient receiving trastuzumab with or without chemotherapy or hormonal therapy for at least 4 months.

• No evidence of disease progression (clinical and / or radiological) for at least 4 months before inclusion in the study and with a life expectancy of at least 3 months.

• Adequate performance status: Eastern Cooperative Oncology Group (ECOG) <2.

• Adequate bone marrow function, liver and kidney

• Proper cardiac function (LVEF within normal limits the center, measured by echocardiography or MUGA).

• The patient must have been informed of the study and must sign and date informed consent document for entry into the trial.

• The patient must be willing and able to comply with study procedures and be available to answer the study questionnaires.

Read More

Exclusion Criteria

• Patients with no advanced breast cancer.
• Breast cancer patients with tumors HER 2-negative.
• The patient has another active malignancy other than breast adenocarcinoma; are excluded the non-melanoma skin cancer or any other properly treated in situ neoplasia. Patients with a history of malignancy, if they bear> 5 years without evidence of disease could be included.
• The patient has uncontrolled brain metastases.
• Concomitant administration, or in the 4 weeks prior to study entry, of other experimental treatment.
• Known hypersensitivity to trastuzumab or to any of its components.
• Patients with severe dyspnea at rest or requiring supplemental oxygen.
• Heart disease or serious medical pathological prevent trastuzumab administration: documented history of congestive cardiac insufficiency (CCI), high-risk arrhythmias uncontrolled angina requiring medication, clinically significant valvular disease, history of myocardial infarction or evidence of transmural infarction on ECG or hypertension poorly controlled.
• Presence of any concomitant serious systemic disease that is incompatible with the study (at the discretion of the investigator).
• The patient is pregnant or lactating. Women of childbearing potential should undergo pregnancy testing blood or urine within 14 days prior to inclusion as institutional rules and use a non-hormonal contraceptive suitable: intrauterine device, barrier method (condom or diaphragm) also used in conjunction with spermicidal cream, total abstinence or surgical sterilization, during treatment with the study drugs and for 6 months following the end of treatment.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm B: T-IV + T-SC device + T-SC vial	Trastuzumab Injection	Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.
Arm A: T-IV + T-SC vial + T-SC device	Trastuzumab Injection	Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.
Arm B: T-IV + T-SC device + T-SC vial	Trastuzumab Injectable Solution	Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.
Arm A: T-IV + T-SC vial + T-SC device	Trastuzumab Injectable Product	Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.
Arm B: T-IV + T-SC device + T-SC vial	Trastuzumab Injectable Product	Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.
Arm A: T-IV + T-SC vial + T-SC device	Trastuzumab Injectable Solution	Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference	Up to 12 weeks	The percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab was analyzed with the answer to the questionnaire C2, question number 39 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of experiences and preferences of the patient.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Subcutaneous Treatment (Vial vs Device Administration) Preference	Up to 12 weeks	The percentage of patients who indicate a preference for the use of SC administration by vial or device was analyzed. This was discussed in the answer to questionaire C3, question number 28 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of the questionnaire of experiences and preferences of the patient.
Percentage of Medical Staff With Intravenous vs. Subcutaneous Preference	Up to 12 weeks	The medical staff satisfaction was analyzed with the answers to question number 33a (Considering all aspects, with what method of administration were you more satisfied? Between Intravenous vs. Subcutaneous: Intravenous; Subcutaneous; No differences) of the questionnaire of experiences and preferences of the medical staff.; Health care professionals were not considered enrolled, but did contribute to this assessment.
Percentage of Medical Staff Subcutaneous Device vs. Vial Preference	Up to 12 weeks	The medical staff satisfaction was analyzed with the answers to question number 33b (Considering all aspects, with what method of administration were you more satisfied? Between Vial vs. Device: Preferred device; Preferred vial; No Preference) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.
Patient Time in Healthcare Unit and Sitting in Chair/Bed	An average of 4 months	Time spent by patient in the healthcare unit: Time between entrance and exit from the healthcare unit.; Time spent by patient sitting in the infusion/treatment chair/bed: Time between sitting and rising from the patient treatment chair/bed The data was collected by qualified observers from site staff that measured the time spent by healthcare professional using a chronometer, and write it down in the paper questionnaires or directly or after in the electronic case report form.
The Number of Participants Who Experienced Adverse Events (AE)	Through study treatment, an average of 12 weeks	Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.

Trial Locations

Locations (27)

Hospital de Mataró; 🇪🇸 Mataró, Barcelona, Spain

Hospital de Manacor; 🇪🇸 Manacor, Illes Balears, Spain

Hospital General Universitario de Granollers; 🇪🇸 Granollers, Barcelona, Spain

Hospital Virgen del Puerto de Plasencia; 🇪🇸 Plasencia, Cáceres, Spain

Hospital Sant Joan Despí Moises Broggi; 🇪🇸 Sant Joan Despí, Barcelona, Spain

Hospital del Mar; 🇪🇸 Barcelona, Spain

Hospital Universitario de Fuenlabrada; 🇪🇸 Fuenlabrada, Madrid, Spain

Hospital Universitario Severo Ochoa; 🇪🇸 Leganés, Madrid, Spain

Hospital General Universitario Gregorio Marañón; 🇪🇸 Madrid, Spain

Hospital Costa del Sol; 🇪🇸 Marbella, Málaga, Spain

Hospital Universitario La Princesa; 🇪🇸 Madrid, Spain

Hospital Universitario Arnau de Vilanova de Lleida; 🇪🇸 Lleida, Spain

Hospital Universitario Miguel Servet; 🇪🇸 Zaragoza, Spain

Hospital Universitario San Joan de Reus; 🇪🇸 Reus, Tarragona, Spain

Hospital Universitario Santa Lucía; 🇪🇸 Cartagena, Murcia, Spain

Hospital Universitario de Salamanca; 🇪🇸 Salamanca, Spain

Hospital Universitario Virgen de la Macarena; 🇪🇸 Sevilla, Spain

Hospital Universitario 12 de Octubre; 🇪🇸 Madrid, Spain

Hospital Virgen de la Salud; 🇪🇸 Toledo, Spain

Hospital Clínico Universitario de Valencia; 🇪🇸 Valencia, Spain

Hospital Nuestra Señora de Sonsoles; 🇪🇸 Ávila, Spain

Hospital Univesitario Quirón Madrid; 🇪🇸 Pozuelo De Alarcón, Madrid, Spain

Hospital Universitario Virgen de las Nieves; 🇪🇸 Granada, Spain

Hospital Germans Trias i Pujol; 🇪🇸 Barcelona, Spain

Hospital Clinic i Provincial; 🇪🇸 Barcelona, Spain

Hospital Universitario Lucus Augusti; 🇪🇸 Lugo, Spain

Hospital Universitario Virgen del Rocío; 🇪🇸 Sevilla, Spain